JAMP Pharma, a Canadian-based pharmaceutical company, has announced the launch of generic guanfacine XR, a medicine that treats attention deficit hyperactivity disorder (ADHD), according to Cision Canada.
The product is bioequivalent to Intuniv XR (guanfacine), which is developed and sold by Takeda Canada Inc. The launch of JAMP’s generic guanfacine offers the same quality and is more affordable, making the treatment more accessible to patients with ADHD.
JAMP aims to offer a wide range of generic products to meet the specific needs of patients in terms of drug size and appearance. In Canada, the cost associated with ADHD is estimated to exceed $7 billion each year so the company intends to produce generic ADHD drugs in the coming years.
Canadian patients and medical professionals can expect more generic ADHD drugs and a reliable supply chain in the furtive.
Guanfacine XR (extended-release) tablets are recommended for the treatment of ADHD in children and teenagers aged between 6 and 17 years. The drug is available in the dosages 1 mg to 4 mg.
Bruno Mäder, President and COO of JAMP, said, “At JAMP Pharma Group, we’re always listening to the needs of patients and healthcare professionals here in Canada. The launch of Guanfacine XR gives children and youth a new ADHD treatment option.”
“We’re excited about our plans to invest in commercializing many generic ADHD drugs in the coming years and enhancing pharmaceutical autonomy in this cutting-edge sector,” he added. “That, combined with our current position as a leader in product launches, makes JAMP Pharma Group more confident and ambitious than ever in aspiring to become Canada’s largest pharmaceutical company in the near future.”
JAMP has enjoyed remarkable growth in the pharmaceutical industry for more than 10 years. It is active in all segments of the pharmaceutical industry – thanks to a portfolio of close to 300 molecules.
In the last three years, Health Canada approved nearly 40 new products of JAMP. It is one of the leading key industry players in generic product launches. The company is broadening the new treatment options available in Canada, even for many specialty drugs. It has a portfolio of nearly 180 over-the-counter (OTC) products, including multivitamins, supplements, and natural products.
